XenoPort to Present at the Wells Fargo Securities Healthcare
Conference

Wells Fargo Healthcare Conference 2013

June 11, 2013 10:30 AM Eastern Daylight Time

SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide
access via the World Wide Web to its presentation at the Wells Fargo
Securities Research & Economics 2013 Healthcare Conference. The live
presentation will occur at 8:15 a.m. Pacific Time (11:15 a.m. Eastern
Time) on Wednesday, June 19, 2013. A replay of the presentation will
also be available.

To access the live presentation via the Web, please go to www.XenoPort.com.
Please connect to the Web site at least 15 minutes prior to the live
presentation to ensure adequate time for any software downloads that may
be necessary to listen to the Webcast.

A replay of the Webcast can be accessed for a minimum of one month and
will be available approximately 24 hours after the live presentation.

About XenoPort

XenoPort, Inc. is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates
for the potential treatment of neurological disorders. Horizant®
(gabapentin enacarbil) Extended-Release Tablets is approved and being
marketed in the United States by XenoPort. Regnite® (gabapentin
enacarbil) Extended-Release Tablets is approved and being marketed in
Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights
to gabapentin enacarbil. XenoPort's pipeline of product candidates
includes potential treatments for patients with Parkinson's disease,
relapsing-remitting multiple sclerosis and psoriasis.